Publications by authors named "Andy Moreno"

Claim this Profile
C
Comprehensive characterization and validation of the Prp-hPFN1 mouse model: Guidelines for preclinical therapeutic testing for ALS.
Kaly A Mueller, Emma G Suneby, Matthew H Ferola, Andy J Moreno, Joshua D Kidd

Neurobiol Dis· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits.
Fernando G Vieira, Theo Hatzipetros, Kenneth Thompson, Andy J Moreno, Joshua D Kidd

IBRO Rep· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS.
Fernando G Vieira, Qinggong Ping, Andy J Moreno, Joshua D Kidd, Kenneth Thompson

PLoS One· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dexpramipexole is ineffective in two models of ALS related neurodegeneration.
Fernando G Vieira, Eva LaDow, Andy Moreno, Joshua D Kidd, Beth Levine

PLoS One· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS.
Theo Hatzipetros, Joshua D Kidd, Andy J Moreno, Kenneth Thompson, Alan Gill

J Vis Exp· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS.
Theo Hatzipetros, Laurent P Bogdanik, Valerie R Tassinari, Joshua D Kidd, Andy J Moreno

Brain Res· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis